misonidazole has been researched along with Cancer of Head in 107 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (23.36) | 18.7374 |
| 1990's | 4 (3.74) | 18.2507 |
| 2000's | 22 (20.56) | 29.6817 |
| 2010's | 48 (44.86) | 24.3611 |
| 2020's | 8 (7.48) | 2.80 |
| Authors | Studies |
|---|---|
| Baltas, D; Fennell, JT; Grosu, AL; Mix, M; Nicolay, NH; Ruf, J; Rühle, A; Stoian, R; Thomsen, AR; Vaupel, P; Wiedenmann, N | 1 |
| Alber, M; Belka, C; La Fougère, C; Nikolaou, K; Paulsen, F; Pfannenberg, C; Reimold, M; Reischl, G; Thorwarth, D; Welz, S; Zips, D | 1 |
| Boeke, S; Bowden, G; Cotton, J; Krueger, MA; Leibfarth, S; Pichler, BJ; Thorwarth, D; Winter, RM; Zips, D | 1 |
| Bak, B; Cegła, P; Cholewinski, W; Kazmierska, J; Malicki, J; Piotrowski, T; Sowinska, A | 1 |
| Baltas, D; Bunea, H; Grosu, AL; Lazzeroni, M; Mix, M; Schiavo, F; Sörensen, A; Stoykow, C; Thomann, B; Toma-Dasu, I; Ureba, A; Wiedenmann, N | 1 |
| Baumann, M; Boeke, S; Gregoire, V; Hofheinz, F; Johansen, J; Krause, M; Löck, S; Mönnich, D; Overgaard, J; Saksø Mortensen, L; Saksø, M; Seidlitz, A; Skripcak, T; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Christophi, C; Fang, C; Gan, H; Lee, ST; Liu, Z; Muralidharan, V; Pathmaraj, K; Sachinidis, J; Scott, AM; Tebbutt, N; Wong, P | 1 |
| Baumann, M; Kotzerke, J; Krause, M; Löck, S; Seidlitz, A; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Fougère, C; Leibfarth, S; Nikolaou, K; Pfannenberg, C; Reischl, G; Schmidt, H; Schwenzer, N; Simoncic, U; Thorwarth, D; Welz, S; Zips, D | 1 |
| Beattie, BJ; Carlin, SD; Grkovski, M; Humm, JL; Lee, NY; Leeman, JE; O'Donoghue, JA; Riaz, N; Schöder, H | 2 |
| Bandurska-Luque, A; Baumann, M; Kotzerke, J; Krause, M; Löck, S; Perrin, R; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Apte, A; Crispin-Ortuzar, M; Deasy, JO; Grkovski, M; Humm, JL; Lee, NY; Oh, JH; Schöder, H | 1 |
| Agarwal, J; Budrukkar, A; Chatterjee, A; Ghosh-Laskar, S; Gupta, T; Kunder, S; Murthy, V; Purandare, N; Rangarajan, V | 1 |
| Baltas, D; Bunea, H; Dasu, A; Grosu, AL; Lazzeroni, M; Toma-Dasu, I | 1 |
| Abolmaali, N; Appold, S; Bandurska-Luque, A; Baumann, M; Haase, R; Kotzerke, J; Krause, M; Löck, S; Richter, C; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K | 1 |
| Gafita, A; Hirata, K; Kroenke, M; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Tamaki, N; Watanabe, S | 1 |
| Cegla, P; Joanna, K; Julian, M; Michal, S; Sebastian, G; Witold, C | 1 |
| Aust, DE; Bandurska-Luque, A; Baretton, GB; Baumann, M; Buchholz, F; Gudziol, V; Kotzerke, J; Krause, M; Linge, A; Löck, S; Nowak, A; Overgaard, J; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K | 1 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Mix, M; Weber, WA; Wiedenmann, N | 1 |
| Alber, M; Kaanders, JH; Mönnich, D; Oyen, WJ; Thorwarth, D; Troost, EG; Zips, D | 1 |
| Haba, R; Hoshikawa, H; Iwasaki, A; Kudomi, N; Maeda, Y; Matsunaga, T; Nishiyama, Y; Norikane, T; Yamamoto, Y | 1 |
| de Clermont-Gallerande, H; Fernandez, P; Hatt, M; Henriques de Figueiredo, B; Lamare, F; Merlin, T; Vimont, D | 1 |
| Astner, ST; Bayer, C; Cheng, X; Maftei, CA; Shi, K; Vaupel, P; Ziegler, SI | 1 |
| Binns, D; Bressel, M; Corry, J; Fisher, R; Hicks, RJ; McArthur, GA; Peters, LJ; Rischin, D; Solomon, B; Trinkaus, ME; Young, RJ | 1 |
| Porceddu, SV | 1 |
| Baumann, M; Bergmann, R; Beuthien-Baumann, B; Brüchner, K; Hessel, F; Kotzerke, J; Krause, M; Mosch, B; Schütze, C; Steinbach, J; Thames, H; Yaromina, A; Zips, D | 1 |
| Giraud, P; Servagi-Vernat, S | 1 |
| Fatema, CN; Kitagawa, Y; Kuge, Y; Nishijima, K; Tamaki, N; Yasuda, K; Yu, W; Zhao, S; Zhao, Y | 1 |
| Aguilera, TA; Giaccia, AJ | 1 |
| Galoforo, S; Grills, IS; Kane, JL; Krueger, SA; Marples, B; Wilson, GD; Wobb, J | 1 |
| Abolmaali, N; Appold, S; Baumann, M; Gudziol, V; Haase, R; Kotzerke, J; Krause, M; Perrin, R; Richter, C; Steinbach, J; Stützer, K; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Mix, M; Nestle, U; Pfeiffer, J; Vach, W; Weber, WA; Wiedenmann, NE | 1 |
| la Fougère, C; Mauz, PS; Mönnich, D; Nikolaou, K; Pfannenberg, C; Reischl, G; Thorwarth, D; Welz, S; Zips, D | 1 |
| Hirata, K; Tamaki, N | 1 |
| Carlin, SD; Gönen, M; Grkovski, M; Humm, JL; Lee, NY; Nehmeh, SA; Schöder, H; Schwartz, J; Zanzonico, PB | 1 |
| Krohn, KA; Muzi, M | 1 |
| Hirata, K; Kasai, K; Kuge, Y; Magota, K; Nishijima, KI; Okamoto, S; Onimaru, R; Shiga, T; Shirato, H; Tamaki, N; Tuchiya, K; Watanabe, S; Yasuda, K | 1 |
| Baumann, M; Mönnich, D; Thorwarth, D; Wack, LJ; Yaromina, A; Zips, D | 1 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Kayser, G; Meyer, PT; Mix, M; Rücker, G; Weber, WA; Werner, M; Wiedenmann, N | 1 |
| Astner, ST; Bayer, C; Gaertner, FC; Nüsslin, F; Shi, K; Vaupel, P; Wilkens, JJ; Ziegler, SI | 1 |
| Krohn, KA; Yeuh, B | 1 |
| Fury, MG; Humm, JL; Jansen, JF; Koutcher, JA; Lee, NY; Pfister, DG; Schöder, H; Shukla-Dave, A; Stambuk, HE; Wang, Y | 1 |
| Humm, JL; Ling, CC; Nehmeh, SA; Wang, K; Yorke, E | 1 |
| Georgi, JC; Guillem, J; Humm, JL; Lee, NY; Narayanan, M; Schöder, H; Wang, W | 1 |
| Kikuchi, M; Senda, M; Shinohara, S; Yamane, T | 1 |
| Bentzen, L; Buus, S; Keiding, S; Mortensen, LS; Munk, OL; Nordsmark, M; Overgaard, J | 1 |
| Abolmaali, N; Baumann, M; Haase, R; Koch, A; Kotzerke, J; Steinbach, J; Zips, D; Zöphel, K | 1 |
| Brown, JM; Carlson, DJ; Chen, ZJ; Keall, PJ; Loo, BW | 1 |
| Astner, ST; Bayer, C; Maftei, CA; Shi, K; Vaupel, P | 1 |
| Fujiwara, K; Hori, SY; Kikuchi, M; Naito, Y; Senda, M; Shinohara, S; Tona, Y; Yamane, T; Yamazaki, H | 1 |
| Bentzen, SM; Bowen, SR; Jeraj, R; Nordsmark, M; van der Kogel, AJ | 1 |
| Hendrickson, K; Krohn, K; Peterson, L; Phillips, M; Rajendran, J; Smith, W | 1 |
| Chen, L; Guan, Y; Kolb, HC; Walsh, JC; Zhang, J; Zhang, Z | 1 |
| Abolmaali, N; Abramyuk, A; Appold, S; Baumann, M; Haase, R; Kotzerke, J; Perrin, R; Steinbach, J; Zips, D; Zöphel, K | 1 |
| Dierckx, RA; Halmos, GB; Langedijk, JA; Pruim, J; Roodenburg, JL; van der Laan, BF; Wedman, J | 1 |
| Anderson, NJ; Chang, JH; Gan, HK; Gong, SJ; Gunawardana, DH; Khoo, V; Lee, ST; Lim Joon, D; O'Keefe, G; Sachinidis, J; Scott, AM; Wada, M | 1 |
| Ito, YM; Kasai, K; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Shirato, H; Tamaki, N; Yasuda, K | 1 |
| Glaholm, J; Watkinson, JC | 1 |
| Büll, U; Coenen, HH; Dimartino, E; Eble, MJ; Gagel, B; Hamacher, K; Maneschi, P; Pinkawa, M; Reinartz, P; Stanzel, S; Westhofen, M; Zimny, M | 1 |
| Bares, R; Dittmann, H; Eschmann, SM; Machulla, HJ; Paulsen, F; Reimold, M; Reischl, G; Welz, S | 1 |
| Alber, M; Eschmann, SM; Paulsen, F; Thorwarth, D | 3 |
| Alber, M; Eschmann, SM; Paulsen, F; Scheiderbauer, J; Thorwarth, D | 1 |
| Binns, D; Corry, J; Fisher, R; Hicks, RJ; Peters, LJ; Porceddu, S; Rischin, D | 1 |
| Buell, U; Coenen, HH; DiMartino, E; Eble, M; Gagel, B; Hamacher, K; Reinartz, P; Westhofen, M; Zimny, M | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, M; Troost, EG; van der Kogel, AJ | 1 |
| Alber, M; Eschmann, SM; Holzner, F; Paulsen, F; Thorwarth, D | 1 |
| Grierson, JR; Krohn, KA; Ng, P; O'Sullivan, J; Peterson, LM; Rajendran, JG; Scharnhorst, J; Schwartz, DL | 1 |
| Bamberg, M; Bares, R; Bedeshem, C; Eschmann, SM; Hehr, T; Machulla, HJ; Paulsen, F | 1 |
| Asadpour, B; Coenen, HH; Demirel, C; DiMartino, E; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Maneschi, P; Pinkawa, M; Piroth, M; Reinartz, P; Scholbach, T; Stanzel, S; Zimny, M | 1 |
| Cai, S; Chan, K; Greco, C; Humm, JL; Lee, NY; Lin, Z; Ling, CC; Mechalakos, JG; Nehmeh, S; Schöder, H; Squire, OD; Zanzonico, PB | 1 |
| Lee, ST; Scott, AM | 1 |
| Erdi, YE; Greco, C; Humm, JL; Larson, SM; Lee, NY; Ling, CC; Mageras, G; Nehmeh, SA; Pham, HS; Schröder, H; Squire, O; Zanzonico, PB | 1 |
| Humm, J; Lee, N; Lin, Z; Ling, CC; Mechalakos, J; Nehmeh, S; Schoder, H | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, ME; Troost, EG; van der Kogel, AJ | 1 |
| Awwad, HK; Barsoum, M; El Badawy, S; El Baki, HA; El Merzabani, M; Ezzat, S; Omar, S; Zaki, A | 1 |
| Onoyama, Y | 1 |
| Dische, S | 1 |
| Cridland, S; Sealy, R | 1 |
| Dar'ialova, SL; Kiseleva, ES | 1 |
| Demange, L; Froissart, D; Nguyen, TD; Panis, X | 1 |
| Kogelnik, HD | 1 |
| Bleehen, NM | 1 |
| Phillips, TL; Stetz, J; Wasserman, TH | 2 |
| Arcangeli, G; Chaplain, G; Gonzalez, D; Horiot, JC; Svoboda, V; Van den Bogaert, W; van der Schueren, E | 1 |
| Dawes, PJ; Henk, JM; Moore, JL; Paterson, IC | 1 |
| Moore, JL; Newman, H; Paterson, IC; Venables, S | 1 |
| Fazekas, JT; Goodman, RL; McLean, CJ | 1 |
| Arcangeli, G; Barocas, A; Mauro, F; Nervi, C; Spanò, M; Tabocchini, A | 1 |
| Kogelnik, HD; Mamoli, B; Reinartz, G; Seitz, W; Stark, H; Szepesi, T; Wessely, P; Wurst, F | 1 |
| Arcangeli, G; de Pauw, M; De Vilhena, M; Horiot, JC; Schraub, S; Svoboda, V; Van den Bogaert, W; van der Schueren, E; van Glabbeke, M | 2 |
| Giuliano, J; Lee, DJ; Moini, M; Westra, WH | 1 |
| D'Costa, I; Fisher, R; Hart, R; Hicks, R; Hughes, P; Peters, L; Rischin, D; Sexton, M; von Roemeling, R | 1 |
| Cooper, J; Curran, WJ; Davis, LW; Fazekas, JT; Laramore, GE; Marcial, VA; Pajak, TF; Rubin, P | 1 |
| Fischer, JJ; Lee, DJ; Order, SE; Pajak, TF; Stetz, J; Weissberg, JB | 1 |
| Cooper, JS; Davis, LW; Fazekas, JT; Marcial, V; Scott, C; Wasserman, T | 1 |
| Davis, L; Fazekas, J; Kramer, S; Marcial, V; Pajak, TF; Rotman, M; Stetz, J; Wasserman, T | 1 |
| Dawes, PT; Henk, JM; Jones, RD; Moore, JL; Paterson, IC | 1 |
| Adams, GE; Bleehen, NM; Dische, S; Freedman, LS; Henk, JM; Honess, DJ | 1 |
| Barthelme, E; Chaplain, G; Chenal, C; Devilhena, M; Horiot, JC; Leonor, J; Raposo, S; Schraub, S; van den Bogaert, W; van der Schueren, E | 1 |
| Barry, L; Cridland, S; Norris, R; Sealy, R | 1 |
| Arcangeli, G; Chaplain, G; Gonzalez, D; Horiot, JC; Svoboda, V; Van den Bogaert, W; van der Schueren, E; Van Tongelen, C | 1 |
8 review(s) available for misonidazole and Cancer of Head
| Article | Year |
|---|---|
Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Topics: Cell Hypoxia; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Multicenter Studies as Topic; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
[Metabolic tailoring in radiotherapy for head and neck cancer].
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Clinical Trials as Topic; Diffusion Magnetic Resonance Imaging; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Misonidazole; Multimodal Imaging; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Tumor Burden | 2014 |
Tumor hypoxia: a new PET imaging biomarker in clinical oncology.
Topics: Biomarkers; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Tumor Hypoxia | 2016 |
Novel imaging approaches to head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Diagnostic Imaging; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Oxygen; Positron-Emission Tomography | 2008 |
Alternative PET tracers in head and neck cancer. A review.
Topics: Amino Acids; Antibodies, Monoclonal; Carbon Radioisotopes; Carcinoma, Squamous Cell; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Nitroimidazoles; Nucleosides; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.
Topics: Animals; Brain Ischemia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Fluorine Radioisotopes; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Misonidazole; Myocardial Ischemia; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stroke | 2007 |
[Electron acceptor compounds as radiation sensitizers of hypoxic cells in human tumors].
Topics: Brain Neoplasms; Combined Modality Therapy; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Metronidazole; Misonidazole; Mouth Neoplasms; Neoplasms; Radiation-Sensitizing Agents; Rectal Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 1984 |
Hypoxic sensitizer and cytotoxin for head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Hypoxia; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Etanidazole; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Mice; Microelectrodes; Misonidazole; Oxygen Consumption; Radiation Tolerance; Radiation-Sensitizing Agents; Survival Rate; Tirapazamine; Treatment Outcome; Triazines | 1996 |
30 trial(s) available for misonidazole and Cancer of Head
| Article | Year |
|---|---|
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Topics: Biomarkers; Cell Hypoxia; Head and Neck Neoplasms; Humans; Hypoxia; Interleukin-6; Misonidazole; Pilot Projects; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck | 2022 |
Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [
Topics: Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Monitoring early response to chemoradiotherapy with
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Time Factors; Tissue Distribution; Treatment Outcome | 2017 |
Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
Topics: Aged; Carcinoma, Squamous Cell; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Burden | 2013 |
Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Cyclin-Dependent Kinase Inhibitor p16; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Neoplasm Proteins; Papillomavirus Infections; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2014 |
Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed | 2015 |
Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Feasibility Studies; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Treatment Outcome; Tumor Burden | 2015 |
Robustness of quantitative hypoxia PET image analysis for predicting local tumor control.
Topics: Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multicenter Studies as Topic; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Squamous Cell Carcinoma of Head and Neck | 2015 |
The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Topics: Adult; Aged; Dose Fractionation, Radiation; Down-Regulation; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Tumor Hypoxia | 2016 |
Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Misonidazole; Neoadjuvant Therapy; Positron-Emission Tomography; Treatment Outcome | 2011 |
pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Topics: Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Misonidazole; Oximetry; Oxygen; Oxygen Consumption; Polarography; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorine Radioisotopes; Germany; Head and Neck Neoplasms; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia.
Topics: Cell Hypoxia; Computer Simulation; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Kinetics; Misonidazole; Models, Biological; Neovascularization, Pathologic; Oxygen; Oxygen Consumption; Radioisotope Dilution Technique; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncolog
Topics: Cell Hypoxia; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Tirapazamine; Treatment Failure; Triazines | 2006 |
A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Peripheral Nervous System Diseases; Radiotherapy; Radiotherapy Dosage; Random Allocation | 1984 |
[Clinical trials of hypoxic cell sensitizer misonidazole].
Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Random Allocation; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1983 |
Clinical trials with hypoxic cell sensitizers-the European experience.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Methods; Misonidazole; Neoplasms; Nitroimidazoles; Urinary Bladder Neoplasms | 1983 |
The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Middle Aged; Misonidazole; Nitroimidazoles; Pilot Projects; Prospective Studies; Radiation-Sensitizing Agents; Random Allocation | 1984 |
Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cobalt Radioisotopes; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Prospective Studies; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy Dosage; Random Allocation | 1984 |
The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Glioma; Head and Neck Neoplasms; Humans; Kinetics; Misonidazole; Phenobarbital; Phenytoin; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 1980 |
Radiation Therapy Oncology Group clinical trials with misonidazole.
Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Glioma; Head and Neck Neoplasms; Humans; Misonidazole; Nausea; Nervous System Diseases; Nitroimidazoles; Radiotherapy Dosage; Random Allocation; Vomiting | 1981 |
The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Topics: Combined Modality Therapy; Head and Neck Neoplasms; Humans; Misonidazole; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 1995 |
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Topics: Female; Head and Neck Neoplasms; Humans; Male; Misonidazole; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Survival Rate | 1995 |
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Middle Aged; Misonidazole; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Tirapazamine; Tomography, Emission-Computed; Triazines | 2001 |
Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report.
Topics: Carcinoma, Squamous Cell; Clinical Protocols; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Misonidazole; Outcome and Process Assessment, Health Care; Radiation-Sensitizing Agents | 1991 |
A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
Topics: Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Multicenter Studies as Topic; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Random Allocation | 1989 |
The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Misonidazole; Multicenter Studies as Topic; United States | 1989 |
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Prognosis; Radiation-Sensitizing Agents; Random Allocation | 1987 |
Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Prognosis; Radiotherapy; Radiotherapy Dosage; Random Allocation | 1986 |
Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Misonidazole; Prospective Studies; Radiation-Sensitizing Agents; Random Allocation | 1986 |
69 other study(ies) available for misonidazole and Cancer of Head
| Article | Year |
|---|---|
Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.
Topics: Animals; Diffusion Magnetic Resonance Imaging; Head and Neck Neoplasms; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Dideoxynucleosides; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Hypoxia | 2020 |
Quantification of Tumor Oxygenation Based on FMISO PET: Influence of Location and Oxygen Level of the Well-Oxygenated Reference Region.
Topics: Head and Neck Neoplasms; Humans; Misonidazole; Oximetry; Oxygen; Positron-Emission Tomography; Tumor Hypoxia; Tumor Microenvironment | 2020 |
Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma.
Topics: Biomarkers; Colorectal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals | 2021 |
Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
Topics: Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Head and Neck Neoplasms; Humans; Inflammation; Misonidazole; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tumor Hypoxia | 2021 |
Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Topics: Contrast Media; Head and Neck Neoplasms; Humans; Kinetics; Magnetic Resonance Imaging; Misonidazole; Positron-Emission Tomography | 2017 |
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2017 |
Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tumor Hypoxia | 2018 |
Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Time Factors; Tumor Hypoxia; Young Adult | 2018 |
Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging.
Topics: Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Misonidazole; Models, Theoretical; Positron-Emission Tomography; Tumor Hypoxia | 2018 |
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Topics: Adult; Aged; Cell Hypoxia; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Squamous Cell Carcinoma of Head and Neck; Tumor Hypoxia | 2019 |
Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiation Tolerance; Radiopharmaceuticals; Tumor Hypoxia | 2019 |
Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose-18F-fluorothymidine- 18F-fluoromisonidazole-PET/CT study and human papillomavirus status in patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Papillomaviridae; Positron Emission Tomography Computed Tomography; Radioactive Tracers | 2019 |
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Topics: Adult; Aged; Cell Hypoxia; Cohort Studies; Female; Fluorine Radioisotopes; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2019 |
Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.
Topics: Cell Hypoxia; Chemoradiotherapy; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Male; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.
Topics: Animals; Carcinoma, Squamous Cell; Computer Simulation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Mice; Microvessels; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tumor Cells, Cultured | 2013 |
Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Tumor Suppressor Protein p53 | 2014 |
Preclinical evaluation of parametric image reconstruction of [18F]FMISO PET: correlation with ex vivo immunohistochemistry.
Topics: Animals; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice; Misonidazole; Positron-Emission Tomography | 2014 |
Insights into the relationship between HPV/p16 status, hypoxia imaging and treatment outcomes in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Cyclin-Dependent Kinase Inhibitor p16; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Neoplasm Proteins; Papillomavirus Infections; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2014 |
Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Radiation; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Random Allocation; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Head and Neck Neoplasms; Heterografts; Humans; Hypoxia; Male; Mice; Misonidazole; Radionuclide Imaging; Radiopharmaceuticals; Tumor Burden | 2014 |
The end of the hypoxic EPOch.
Topics: Anemia; Blood Transfusion; Carcinoma, Squamous Cell; Cell Hypoxia; Clinical Trials as Topic; Erythropoietin; Etanidazole; Female; Head and Neck Neoplasms; Humans; Male; Misonidazole; Radiation-Sensitizing Agents; Receptors, Erythropoietin; Treatment Failure; Uterine Cervical Neoplasms | 2015 |
The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Coloring Agents; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Heterografts; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Nitroimidazoles; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.
Topics: Algorithms; Animals; Carcinoma, Squamous Cell; Cohort Studies; Colorectal Neoplasms; Head and Neck Neoplasms; HT29 Cells; Humans; Hypoxia; Image Processing, Computer-Assisted; Misonidazole; Neoplasm Transplantation; Perfusion; Radionuclide Imaging; Radiopharmaceuticals; Rats; Reproducibility of Results; Retrospective Studies; ROC Curve | 2016 |
Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.
Topics: Animals; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Misonidazole; Radionuclide Imaging; Radiopharmaceuticals | 2016 |
Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: A question of O2 consumption?
Topics: Animals; Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Computer Simulation; Feasibility Studies; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Hypoxia; Mice, Nude; Misonidazole; Models, Biological; Neoplasm Transplantation; Nitroimidazoles; Oxygen Consumption; Platelet Endothelial Cell Adhesion Molecule-1; Tumor Microenvironment | 2016 |
Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Immunohistochemistry; Ku Autoantigen; Male; Middle Aged; Misonidazole; Papillomavirus Infections; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Hypoxia | 2016 |
Matching the reaction-diffusion simulation to dynamic [
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Diffusion; Female; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, Nude; Misonidazole; Models, Biological; Neoplasms, Squamous Cell; Oxygen; Positron-Emission Tomography; Tumor Hypoxia; Tumor Microenvironment | 2017 |
Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Topics: Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neovascularization, Pathologic; Observer Variation; Oxygen; Perfusion Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tumor Hypoxia | 2017 |
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric | 2010 |
Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET.
Topics: Acute Disease; Algorithms; Cell Hypoxia; Chronic Disease; Computer Simulation; Head and Neck Neoplasms; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Misonidazole; Models, Biological; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique | 2009 |
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.
Topics: Aged; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Neoplasm Staging; Plasma; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow | 2010 |
Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode.
Topics: Biosensing Techniques; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Hypoxia; Microchemistry; Microelectrodes; Misonidazole; Neoplasms; Oxygen; Positron-Emission Tomography; Sarcoma; Soft Tissue Neoplasms | 2010 |
Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
Topics: Carcinoma, Small Cell; Female; Head and Neck Neoplasms; Humans; Image Enhancement; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Time Factors | 2011 |
Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.
Topics: Algorithms; Capillaries; Cell Hypoxia; Cell Survival; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Linear Models; Male; Misonidazole; Oxygen Consumption; Partial Pressure; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Failure | 2011 |
Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.
Topics: Acute Disease; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chronic Disease; Disease Progression; Head and Neck Neoplasms; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Mice; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Transplantation, Heterologous | 2011 |
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.
Topics: Biological Transport; Cell Hypoxia; Coordination Complexes; Copper Radioisotopes; Electrochemistry; Head and Neck Neoplasms; Humans; Misonidazole; Models, Biological; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radioactive Tracers; Reproducibility of Results; Thiosemicarbazones; Time Factors | 2011 |
Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
Topics: Cell Hypoxia; Head and Neck Neoplasms; Humans; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated | 2011 |
¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Hypoxia; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Nitroimidazoles; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles | 2012 |
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
Topics: Aged; Cell Hypoxia; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies | 2012 |
Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Cohort Studies; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Models, Biological; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2013 |
High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Topics: Adult; Aged; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Nuclear Medicine; Positron-Emission Tomography; Prognosis; Radiation Oncology; Radiopharmaceuticals; Reproducibility of Results; Time Factors | 2013 |
Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Cell Hypoxia; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Etanidazole; Head and Neck Neoplasms; Humans; Misonidazole; Niacinamide; Vasodilator Agents | 2003 |
Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Kinetics; Male; Middle Aged; Misonidazole; Models, Statistical; Positron-Emission Tomography; Radiation-Sensitizing Agents; Software; Treatment Outcome | 2005 |
FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Neoplasm Metastasis; Oxygen; Polarography; Positron-Emission Tomography; Reference Standards | 2006 |
Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging | 2006 |
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Topics: Aged; Cell Hypoxia; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2006 |
Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Misonidazole; Multivariate Analysis; Positron-Emission Tomography; Survival Analysis | 2006 |
A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations.
Topics: Algorithms; Cell Hypoxia; Head and Neck Neoplasms; Humans; Misonidazole; Models, Biological; Oxygen; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Burden | 2007 |
Hypoxia dose painting by numbers: a planning study.
Topics: Cell Hypoxia; Feasibility Studies; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2007 |
Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Kinetics; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Radiation-Sensitizing Agents | 2007 |
pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle o
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Misonidazole; Oxygen Consumption; Polarography; Positron-Emission Tomography; Prognosis; Ultrasonography, Doppler, Color | 2007 |
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Topics: Cell Hypoxia; Feasibility Studies; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Radiation-Sensitizing Agents; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2008 |
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Topics: Aged; Cell Hypoxia; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2008 |
The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
Topics: Cell Hypoxia; Feasibility Studies; Follow-Up Studies; Head and Neck Neoplasms; Humans; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2008 |
Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Topics: Animals; Autoradiography; Biomarkers, Tumor; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Misonidazole; Nitroimidazoles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Erythema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Peripheral Nervous System Diseases; Pilot Projects; Radiotherapy Dosage | 1983 |
[Radiosensitization of hypoxic tumor cells with special reference to head and neck cancers].
Topics: Half-Life; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents | 1983 |
The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of C
Topics: Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Pilot Projects; Prognosis; Radiotherapy Dosage | 1982 |
Clinical trials of misonidazole in the United States.
Topics: Drug Evaluation; Head and Neck Neoplasms; Humans; Misonidazole; Neoplasm Metastasis; Neoplasms; Nervous System Diseases; Nitroimidazoles | 1981 |
Pilot study of radiotherapy with misonidazole in head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nervous System Diseases; Nitroimidazoles; Pilot Projects; Radiotherapy Dosage | 1981 |
Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Half-Life; Head and Neck Neoplasms; Humans; Kinetics; Misonidazole; Nitroimidazoles; Phenytoin; Time Factors | 1981 |
The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02).
Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Nitroimidazoles; Paresthesia; Pharyngeal Neoplasms; Prognosis | 1981 |
Multiple daily fractionation (MDF) radiotherapy in association with hyperthermia and/or misonidazole: experimental and clinical results.
Topics: Animals; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Hyperthermia, Induced; Lymphatic Metastasis; Mice; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Radiation Dosage; Radiotherapy; Time Factors | 1980 |
[Clinical experience with daily doses of misonidazole (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nervous System; Nitroimidazoles; Time Factors | 1980 |
Is misonidazole induced neurotoxicity permanent.
Topics: Head and Neck Neoplasms; Humans; Misonidazole; Nervous System Diseases; Pilot Projects | 1988 |
Does initial haemoglobin level modify the efficacy of radiosensitizers? An analysis of the MRC misonidazole studies in head and neck cancer and cervix cancer.
Topics: Combined Modality Therapy; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Misonidazole; Prognosis; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 1987 |
Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Topics: Follow-Up Studies; Head and Neck Neoplasms; Humans; Misonidazole; Neoplasm Staging; Nitroimidazoles; Pilot Projects; Radiotherapy Dosage; Time Factors | 1985 |